TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients
Brief Summary: The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.


Options:
A: Arm Label: Sodium Zirconium Cyclosilicate (ZS) 5g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 5g | Arm Label: Sodium Zirconium Cyclosilicate (ZS) 10g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 10g | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 5g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 5g | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 10g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 10g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sodium Zirconium Cyclosilicate (SZC); Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (SZC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sodium Zirconium Cyclosilicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS); Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS)
D: Arm Label: patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): patiromer | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Healthy Children 4 to 8 Years of Age
Brief Summary: The goal of our research is to provide data to enhance the development of nutritional guidelines, especially as related to mineral nutrition, in children. Using human experimentation, we are studying methods of delivering the key minerals of calcium, zinc and iron in the diet so as to optimize health outcomes. We will conduct a controlled trial of vitamin D supplementation to assess the effects of vitamin D status on calcium absorption in small children. We will evaluate the effects of differing intakes of zinc on zinc and copper absorption. These studies will utilize stable isotope techniques so as to provide accurate, practically applicable information which may be obtained from the study populations in a safe manner. These data will have global application and provide a strong basis for evidence-based nutritional recommendations to be developed.

Objective #1: To evaluate the effects of supplemental vitamin D in enhancing calcium absorption in healthy children 4 to 8 yrs of age.

Objective #2: Assess the absorption of magnesium and zinc in healthy children 4 to 8 yrs of age.


Options:
A: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo, Vitamin D
B: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm A; Type: N/A; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: Arm B; Type: N/A; Interventions: Dietary Supplement: 2000 IU vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): Arm A | Intervention Type: DIETARY_SUPPLEMENT; Name: 2000 IU vitamin D3; Assigned to Arm(s): Arm B
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: daily vitamin D supplement, Other: Placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: daily vitamin D supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: daily vitamin D supplement; Assigned to Arm(s): Placebo, Vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial
Brief Summary: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. It may progress to cirrhosis and liver cancer. At present, there is no approved drug for NAFLD. Although healthy diet and exercise is often recommended, there is little supportive evidence. Therefore, the investigators plan to conduct a randomized controlled trial comparing a low glycemic index dietary intervention program and simple lifestyle advice in NAFLD patients. The primary endpoint is resolution of NAFLD. Non-invasive tests will be used to assess the study subjects. Proton-magnetic resonance spectroscopy is used to quantify hepatic triglyceride content, and transient elastography is used to quantify liver fibrosis.


Options:
A: Arm Label: Glucose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Glucose | Arm Label: Fructose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Fructose | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucose; Assigned to Arm(s): Glucose | Intervention Type: DIETARY_SUPPLEMENT; Name: Fructose; Assigned to Arm(s): Fructose
B: Arm Label: Carbohydrate-restricted diet; Type: EXPERIMENTAL; Interventions: Other: Carbohydrate-restricted diet | Arm Label: Control, low-fat diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control, low-fat diet | Intervention Type: OTHER; Name: Carbohydrate-restricted diet; Assigned to Arm(s): Carbohydrate-restricted diet | Intervention Type: OTHER; Name: Control, low-fat diet; Assigned to Arm(s): Control, low-fat diet
C: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise
D: Arm Label: Low glycemic index dietary intervention program; Type: ACTIVE_COMPARATOR; Interventions: Other: Low glycemic index dietary intervention program | Arm Label: Simple lifestyle advice; Type: PLACEBO_COMPARATOR; Interventions: Other: simple lifestyle advice | Intervention Type: OTHER; Name: Low glycemic index dietary intervention program; Assigned to Arm(s): Low glycemic index dietary intervention program | Intervention Type: OTHER; Name: simple lifestyle advice; Assigned to Arm(s): Simple lifestyle advice

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain
Brief Summary: The purpose of this study is to investigate the best way to evaluate patients with chest pain in the emergency department. It compares types of cardiac tests performed while receiving treatment in an observation unit. Patients will either undergo cardiac MRI testing or conventional care testing. Patients treated in the conventional care testing group will undergo the testing their doctor determines is best for them. All patients will undergo follow up to find out if they have had any heart related events.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: OU - Cardiac MRI | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: OU - Conventional Care Testing | Intervention Type: OTHER; Name: OU - Cardiac MRI; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: OU - Conventional Care Testing; Assigned to Arm(s): 2
B: Arm Label: Emergency Department (ED) Observation unit; Type: EXPERIMENTAL; Interventions: Other: Observation unit care, coupled with cardiac MRI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Observation unit care, coupled with cardiac MRI; Assigned to Arm(s): Emergency Department (ED) Observation unit
C: Arm Label: Inpatient Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CDU-CMR Protocol; Type: EXPERIMENTAL; Interventions: Other: Clinical decision unit care, coupled with cardiac MRI | Intervention Type: OTHER; Name: Clinical decision unit care, coupled with cardiac MRI; Assigned to Arm(s): CDU-CMR Protocol
D: Arm Label: HEART Pathway; Type: EXPERIMENTAL; Interventions: Other: HEART Pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: HEART Pathway; Assigned to Arm(s): HEART Pathway

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators' aim is to determine whether probiotic and prebiotic treatment plus lifestyle advice is more effective in reducing hepatic fat content than lifestyle advice alone in patients with Nonalcoholic Fatty Liver Disease (NAFLD).


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention | Arm Label: Life style intervention, pioglitazone; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: pioglitazone | Arm Label: Life style intervention, berberine; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: berberine | Intervention Type: BEHAVIORAL; Name: Life style intervention; Assigned to Arm(s): Life style intervention, berberine, Life style intervention, pioglitazone, Lifestyle intervention | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Life style intervention, pioglitazone | Intervention Type: DRUG; Name: berberine; Assigned to Arm(s): Life style intervention, berberine
B: Arm Label: TREATED GROUP; Type: EXPERIMENTAL; Interventions: Drug: Hydroxytyrosol plus Vitamin E | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxytyrosol plus Vitamin E; Assigned to Arm(s): TREATED GROUP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP
C: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators' aim is to determine whether probiotic and prebiotic treatment plus lifestyle advice is more effective in reducing hepatic fat content than lifestyle advice alone in patients with Nonalcoholic Fatty Liver Disease (NAFLD).


Options:
A: Arm Label: Rifaximin; Type: EXPERIMENTAL; Interventions: Drug: Rifaximin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rifaximin; Assigned to Arm(s): Rifaximin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Diet advices; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimal Diet | Arm Label: Diet advices + VSL-3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: VSL#3® probiotic blend | Arm Label: Diet advices + 5203-L; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AISA-5203-L fruit extracted terpene | Arm Label: Diet advices + Argan oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Argan oil | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3® probiotic blend; Assigned to Arm(s): Diet advices + VSL-3 | Intervention Type: DIETARY_SUPPLEMENT; Name: AISA-5203-L fruit extracted terpene; Assigned to Arm(s): Diet advices + 5203-L | Intervention Type: DIETARY_SUPPLEMENT; Name: Argan oil; Assigned to Arm(s): Diet advices + Argan oil | Intervention Type: BEHAVIORAL; Name: Optimal Diet; Assigned to Arm(s): Diet advices
C: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
D: Arm Label: VSL#3; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): VSL#3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma
Brief Summary: Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.


Options:
A: Arm Label: Surgical Group; Type: EXPERIMENTAL; Interventions: Drug: PD 0332991 (pre-surgery), Drug: PD 0332991, Procedure: Resection as clinical care | Arm Label: Non-surgical group; Type: EXPERIMENTAL; Interventions: Drug: PD 0332991 | Intervention Type: DRUG; Name: PD 0332991 (pre-surgery); Assigned to Arm(s): Surgical Group | Intervention Type: DRUG; Name: PD 0332991; Assigned to Arm(s): Non-surgical group, Surgical Group | Intervention Type: PROCEDURE; Name: Resection as clinical care; Assigned to Arm(s): Surgical Group
B: Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib
C: Arm Label: ADV-TK/GCV; Type: EXPERIMENTAL; Interventions: Biological: ADV-TK/GCV | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: systemic chemotherapy | Intervention Type: BIOLOGICAL; Name: ADV-TK/GCV; Assigned to Arm(s): ADV-TK/GCV | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Control group | Intervention Type: DRUG; Name: systemic chemotherapy; Assigned to Arm(s): Control group
D: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Study of a Computer Stop Order Versus Routine Practice When Trimethoprim/Sulfamethoxazole is Ordered Concurrently With Warfarin
Brief Summary: To determine if a computerized stop order will reduce the number of concurrent trimethoprim/sulfamethoxazole and warfarin orders accepted through the inpatient electronic ordering system while a patient is hospitalized.


Options:
A: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care
C: Arm Label: Controls ("not tested"); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention ("tested"); Type: ACTIVE_COMPARATOR; Interventions: Genetic: Pharmacogenetic testing | Intervention Type: GENETIC; Name: Pharmacogenetic testing; Assigned to Arm(s): Intervention ("tested")
D: Arm Label: computerized alert; Type: EXPERIMENTAL; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Arm Label: 2 Current practice; Type: OTHER; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole and Warfarin; Assigned to Arm(s): 2 Current practice, computerized alert

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Study of a Computer Stop Order Versus Routine Practice When Trimethoprim/Sulfamethoxazole is Ordered Concurrently With Warfarin
Brief Summary: To determine if a computerized stop order will reduce the number of concurrent trimethoprim/sulfamethoxazole and warfarin orders accepted through the inpatient electronic ordering system while a patient is hospitalized.


Options:
A: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
C: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
D: Arm Label: computerized alert; Type: EXPERIMENTAL; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Arm Label: 2 Current practice; Type: OTHER; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole and Warfarin; Assigned to Arm(s): 2 Current practice, computerized alert

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and efficacy of carisbamate (800 and 1200 mg/day) in patients with diabetic neuropathic pain.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate 800 mg/d | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate 1,200 mg/d | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin 300 mg/d | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin 300 mg/d; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Carisbamate 800 mg/d; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Carisbamate 1,200 mg/d; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 004
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
C: Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin
D: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A